Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. [electronic resource] by
- Beije, N
- Kraan, J
- Taal, W
- van der Holt, B
- Oosterkamp, H M
- Walenkamp, A M
- Beerepoot, L
- Hanse, M
- van Linde, M E
- Otten, A
- Vernhout, R M
- de Vos, F Y F
- Gratama, J W
- Sleijfer, S
- van den Bent, M J
Producer: 20150930
In:
British journal of cancer vol. 113
Availability: No items available.
|